239 filings
Page 9 of 12
8-K
mk6ekbp2kk0g n1o
25 Feb 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:18pm
8-K
zkfj35u7
4 Jan 19
Other Events
5:03pm
8-K
45w7oxq b3
3 Jan 19
Other Events
6:45am
8-K
vis1dos4ngvdysln 5a
4 Dec 18
Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer
4:47pm
8-K
l0s9y
14 Nov 18
Results of Operations and Financial Condition
12:00am
8-K
a9afnpc30 wd
9 Oct 18
Entry into a Material Definitive Agreement
4:52pm
8-K
xldzp391 3h6
1 Oct 18
Departure of Directors or Certain Officers
12:00am
8-K
vn4zdkq k03az
17 Aug 18
Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates
5:02pm
8-K
omxujjho72os f5jv3jl
13 Aug 18
Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019
4:37pm
8-K
1ybzkj
15 Jun 18
Submission of Matters to a Vote of Security Holders
4:04pm
8-K
f6vuyz
1 Jun 18
Entry into a Material Definitive Agreement
5:04pm
8-K
d3ny qx8f
21 May 18
Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients
4:49pm
8-K
7admaktf
21 May 18
Other Events
2:21pm
8-K
x8pyu2qjm3f6h gs
17 May 18
Amendments to Articles of Incorporation or Bylaws
4:50pm
8-K
fvxh e6uh
17 May 18
Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
4:36pm
8-K
aichoilaz
5 Apr 18
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to be Presented in a Plenary Session at American Urological Association Annual Meeting
12:00am
8-K
dgyv6pmq q0a13dgd
5 Apr 18
Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
12:00am
8-K
rk5isz8
23 Mar 18
Entry into a Material Definitive Agreement
12:00am
8-K
pf8vo98leo6olc
23 Mar 18
Other Events
12:00am
8-K
eaj0 ntixs2zi
13 Mar 18
Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer
12:00am